WILEX AG successfully completes rights issue
| PDF Download
Munich, Germany, 08 April 2015 – The shareholders of WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE) exercised their subscription and oversubscription rights for all of the 1,486,732 new no-par value bearer shares for EUR 2.80 per share by the end of the subscription period on 07 April 2015. As a result, the Executive Management Board resolved with the approval of the Supervisory Board to set the total volume of the rights issue at 1,486,732 new shares.
Shareholders exercised subscription rights for a total of 582,240 new shares. A total of 904,492 shares were available under shareholders’ oversubscription rights which have been fully placed to the shareholders through the custodian banks within the transaction. The Company’s main shareholder – dievini Hopp BioTech holding GmbH & Co. KG, Walldorf – exercised all of its subscription rights and subscribed to more shares under oversubscription.
WILEX AG plans to use the gross proceeds of approximately EUR 4.16 million from the rights issue to finance the further development of the ADC technology, in particular the GMP transfer of the drug production, as well as to enhance its equity.
Following the entry of the capital increase in the Commercial Register – which is scheduled for the next few days – the total number of WILEX shares issued will increase to 9,305,608. The subscribed and allocated new shares are expected to be delivered on 13 April 2015, however at the earliest after they have been listed on the stock exchange in the regulated market (Prime Standard). Trading of the new shares on the stock exchange is also scheduled to commence on 13 April 2015. Due to the different dividend entitlement the new shares will be traded separately with the ISIN DE000A14KND2 / WKN A14KND until the planned inclusion of the new shares in the existing stock exchange listing (after the AGM on 30 July 2015). The sole lead manager of the transaction was Baader Bank AG, Unterschleissheim.
About WILEX and Heidelberg Pharma
WILEX AG is a biopharmaceutical company which has a ready for partnering portfolio of antibody-based diagnostic and therapeutic Phase III product candidates for the detection and targeted treatment of clear cell renal cell carcinoma. Research and development now focus on the operations of its subsidiary Heidelberg Pharma GmbH in Ladenburg, which primarily advances the development of the innovative platform technology for antibody drug conjugates (ADC technology) and offers preclinical services. WILEX is listed at the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / Symbol WL6. More information is available at www.wilex.com.
Tel.: +49 (0)89-41 31 38-29
Grillparzerstr. 10, 81675 Munich
MC Services AG
Katja Arnold (CIRO)
Tel.: +49-89-210 228-40
This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will”, “should”, “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.